Glaxo CFO Says Prioritizing R&D for Product Growth

The transcript discusses the perception of Glaxo as uninspiring and the company's disagreement with this view. It highlights the progress made in recent quarters, focusing on new launches in respiratory, HIV, and vaccines, as well as cost savings and restructuring efforts. The company emphasizes its focus on R&D prioritization to drive significant product launches and outlines upcoming key launches, including treatments for shingles and HIV.

What is the speaker's stance on the description of the company as 'uninspiring'?

What does the speaker suggest about the past range of launches?